Slide 1: Full Year Results, 12 months ended 30 June 2004
COMPUMEDICS | ‘Defining Life's Signals’ Full Year Results 12 months ended 30 June, 2004
Slide 2: Outline
COMPUMEDICS™ Defining Lifes Signals’ Outline @ Financial Highlights FYE June 2004 @® Strategy @® Moving Forward
Slide 3: Financial Highlights FYE June 2004 - Profit
COMPUMEDICS” “Defining Lifes Signals’ Financial Highlights FYE June 2004 PROFIT @ Record, positive NPAT AUD$2.4M ($3.5m at last year’s FX rates). @ EBITDA grew 55% over the previous year to AUD$2.9M (90% growth to $4.0m at last year’s FX rates). @ The above results were achieved with the expensing o
Slide 4: Financial Highlights FYE June 2004 - Revenue
COMPUMEDICS” “Defining Lifes Signals’ Financial Highlights FYE June 2004 REVENUE Record revenues of $34m ($39.4M at last year’s FX rates). Record USA revenues of USD$12.8M. In US dollar terms, USA grew by 35% and Europe by 20% from the previous year ended June 2003. Underlying revenue growth was 23%
Slide 5: Financial Highlights FYE June 2004 - Cash and Growth
COMPUMEDICS” “Defining Lifes Signals’ Financial Highlights FYE June 2004 CASH @ Positive operating and net cash at $2.6m and $1.0m respectively for the year. GROWTH @ Europe business strengthened and is now ready for execution of growth strategy similar to the USA with the building of our sales and
Slide 6: Financial Highlights FYE June 2004 - Cost Controls
COMPUMEDICS” “Defining Lifes Signals’ Financial Highlights FYE June 2004 COST CONTROLS @ = Inventory reduced from $8.4m (26% of ’03 revenue) to $6.5m (19% of 03 revenue). @ = Inventory Turns improved from 2.1 to 3.0 turns ( being a 43% improvement). e Margins improve from 56% to 59% despite strong A
Slide 7: Historical Sales Graph
COMPUMEDICS” “Defining Lifes Signals’ Historical Sales Graph AU$m 30, = 25) 20; ‘oo = ‘01 Ol Export Sales & Domestic Sales 4 Other Income
Slide 8: Performance Comparatives - Revenue
COMPUMEDICS” “Defining Lifes Signals’ Performance Comparatives - Revenue AU$m 40 35 32.1 30 5 25 4 2003 Revenue 2004Revenue 2004 Revenue at '03 FX rates
Slide 9: Performance Comparatives - EBITDA
COMPUMEDICS” “Defining Lifes Signals’ Performance Comparatives - EBITDA AU$m 4.5 4-0 4 — 3.5 2003 EBITDA 2004EBITDA 2004 EBITDA at ‘03 FX Rates
Slide 10: Strong growth continues in USA
COMPUMEDICS” ‘Defining Lifes Signals’ Strong growth continues in USA 2003 Europe aa 14% 2004 Australia ae RY °F ° . i 10% USA . 52% Australia 12% 55% 10
Slide 11: Performance relative to PCP
COMPUMEDICS” “Defining Lifes Signals’ Performance relative to PCP 12 mths to | 12 mths to | 12 mths to $Am June 30 June 30 June 30 % change 2002 2003 2004 Operating 19.8 32.1 34.0 6% Revenue EBITDA (0.9) 1.9 2.9 55% EBIT (2.4) (18.8) 2.4 nia Profit after Tax (1.9) (18.6) 2.4 nia Gross Margin 64% 57%
Slide 12: Balance Sheet relative to PCP
COMPUMEDICS” ‘Defining Lifes Signals’ Balance Sheet relative to PCP June 2004 June 2003 A$’000 A$’000 CURRENT ASSETS Cash assets 6,352 5,366 Receivables 10,239 8,624 Inventories 6,481 8,416 Other 69 180 Total current assets 23,141 22,586 NON CURRENT ASSETS Property, plant and equipment 1,368 1,176 T
Slide 13: A Big Market to Grow In
COMPUMEDICS” “Defining Lifes Signals’ A Big Market to Grow In Estimated aiabal marke! value = AUD 21 billion HON Gt feu 13
Slide 14: Strategy Working
COMPUMEDICS” ‘Defining Lifes Signals’ Strategy Working Building a global medical diagnostic company @ With Compumedics’ core strategic edge being Sleep Diagnostics and @ Leveraging this technology into related fields including Neurosciences and Cardiology. 14
Slide 15: Moving Forward: Business
COMPUMEDICS” “Defining Lifes Signals’ Moving Forward : Business Revenues expected to be between $38million and $42million for year ended June 30, 2005. Earnings after tax expected to be between $3 million and $4 million for year ended June 30, 2005. Revenue in the second half of 2005 expected to be
Slide 16: Moving Forward: Technologies
COMPUMEDICS “Defining Lifes Signals’ Moving Forward : Technologies Curry 5.0 Siesta802 ComperioDQ_ Stim il ® Strong product pipelines in all CMP divisions. @ Medical Innovation breakthroughs now approaching patent and clinical proof of concept phase. é wis 16
Slide 17: Recap
COMPUMEDICS “Defining Lifes Signals’ Recap Returned to profitability at $2.4M. Positive cash position. Sales growth strong. Big boost in operational efficiency and more to come. Strong product pipeline and Medical innovation breakthroughs on the horizon. USA continues to grow strongly (USA grew 35%
Slide 18: Strategy in place and working...Growth Ahead
COMPUMEDICS™ Defining Life's Signals’ Strategy in place and working...Growth Ahead COMPUMEDICS COMPUMEDICS COMPUMEDICS COMPUMEDICS NeuroMedical Slee 19) Neuroscience Neuroscan Supplies